Journal of Cancer Research


The Development of LPPC in PAS in Blood Transfusion Centre

Jongkol Akahat, Thipaporn Jaroonsirimaneekul, Nuanchan Mungkhunkhamchaw, Kutcharin Phunikhom.

Background and Objective: Transfusion support in cancer patients is vital for their survival. Platelets, in particular, are necessary to prevent serious bleeding. Platelet additive solutions (PAS) are crystalloid nutrient media used in place of plasma for platelet storage. They replace 60-70% of plasma in platelet components. So the amount of storage plasma can be decreased. Platelet stored in PAS have been demonstrated to have a lower risk for allergic transfusion reactions and appeared to have equivalent clinical efficacy for controlling bleeding, compared to platelets stored in 100% plasma. We try to bring PAS to replace plasma in making leukocyte poor platelet concentrates (LPPC) compared with conventional methods that use plasma, 1 bag of total buffy coat 4 units. 

Objective: The objective of this study was to compare LPPC in PAS and the traditional LPPC in order to prepare LPPC in PAS in our routine work.

Methods: PAS and plasma using a ratio of 65:35 in accordance with the standard reference. Then LPPC in PAS were measured for the volume, content of platelet concentrates, white blood cell contamination and the titer of anti-A and anti-B compared to traditional methods.

Results: LPPC in PAS in the first trial had volumes 304 ml, content of platelet concentrates 2.8X1011 cells/unit and had 0.1X109 white blood cells contamination. LPPC from traditional methods had volumes 324 ml, contents of platelet concentrates 3.9X1011 cells/unit and had 0.1 X109 white blood cells contamination. The platelet yields showed significant different (p>0.1). In the second trial, LPPC in PAS had volumes 300 ml, content of platelet concentrates 3.6X1011 cells/unit and had 0.2X109 white blood cells contamination. It’s not significant different from the traditional method (p<0.1). The titer of anti-A and anti-B in LPPC in PAS is less than or equal to 64, all of which are classified as low titer, but LPPC from the traditional way with a titer of anti-A and anti-B over 64 about 20%.

Conclusion: All of LPPC in PAS are classified as low titer, which led to the patient at any group. This would make the platelet concentrates inventory more flexible. Content of platelet concentrates and white blood cells contamination from LPPC in PAS provides reached the recommended quality of Council of Europe (EU) and National Blood Centre, Thai Red Cross Society (TRC).